普米克气雾剂结合孟鲁司特治疗小儿哮喘疗效及不良反应分析  

Analysis of efficacy and adverse reactions of pumic aerosol combined with montelukast in the treatment of pediatric asthma

作　　者：谢贵会 XIE Guihui(Department of Pediatrics,Zaozhuang Maternal and Child Health Care Hospital,Zaozhuang,Shandong,277100,China)

机构地区：[1]枣庄市妇幼保健院儿一科,山东枣庄277100

出　　处：《当代医学》2022年第28期69-72,共4页Contemporary Medicine

摘　　要：目的探究普米克气雾剂联合孟鲁司特治疗小儿哮喘的临床疗效及不良反应。方法选取2019年1月至2021年1月本院收治的150例小儿哮喘患儿作为研究对象,采用“信封法”分为对照组和观察组,每组75例。对照组采用普米克气雾剂治疗,观察组采用普米克气雾剂联合孟鲁司特治疗,比较治疗前后两组肺功能指标[第1秒用力呼气容积(FEV_(1))、第1秒用力呼气容积与用力肺活量的比值(FEV_(1)/FVC)、最大呼气流量(PEF)]、炎症因子[白细胞介素-17(IL-17)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)]水平、临床疗效及不良反应发生情况。结果治疗前,两组FEV_(1)、FEV_(1)/FVC、PEF比较差异无统计学意义;治疗后,两组FEV_(1)、FEV_(1)/FVC、PEF均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组IL-17、hs-CRP、TNF-α水平比较差异无统计学意义;治疗后,两组IL-17、hs-CRP、TNF-α水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为97.33%,高于对照组的86.67%,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论普米克气雾剂联合孟鲁司特治疗小儿哮喘可提高临床疗效,安全性较高,值得临床推广应用。Objective To investigate the clinical efficacy and adverse reactions of primic aerosol combined with montelukast in the treatment of pediatric asthma.Methods A total of 150 pediatric children with asthma admitted to our hospital from January 2019 to January 2021 were selected as research subjects,and thy were divided into control group and observation group according to the"envelope method",with 75 children in each group.The control group was treated with pumic aerosol,and the observation group was treated with pumic aerosol combined with montelukast,and the pulmonary function indexes(forced expiratory volume in one second[FEV_(1)],forced expiratory volume in one second to forced vital capacity[FEV_(1)/FVC],maximum expiratory flow[PEF]),inflammatory factors(interleukin-17[IL-17],hypersensitivity C-reactive protein[hs-CRP],tumor necrosis factor-α[TNF-α])levels before and after treatment,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference of FEV_(1),FEV_(1)/FVC and PEF between the two groups;after treatment,FEV_(1),FEV_(1)/FVC and PEF in the two groups were higher than those before treatment,and the observation group was higher than the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of IL-17,hs-CRP and TNF-αbetween the two groups;after treatment,the levels of IL-17,hs-CRP and TNF-αof the two groups were lower than before treatment,and the observation group was lower than the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 97.33%,which was higher than 86.67%of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Promik aerosol combined with montelukast in the treatment of pediatric asthma can improve the clin

关 键 词：普米克气雾剂 孟鲁司特 小儿哮喘 炎症因子 肺功能 

分 类 号：R725.6[医药卫生—儿科]